# US 6,730,707 B2 · Method for reducing intraocular pressure using indole derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,707 B2
- Document ID: US6730707B2
- Status: Granted
- Kind: B2
- Application number: 09/915,486
- Filed: 2001-07-25
- Published: 2002-03-28
- Granted: 2004-05-04
- Earliest claimed: 2000-07-28
- Assignees: Inspire Pharmaceuticals, Inc.; Universidad Complutense De Madrid
- Inventors: Jesus J. Pintor; Maria A. Peral; Ward M. Peterson; Robert Plourde, Jr.; Edward G. Brown; Benjamin R. Yerxa
- Web page: https://patentgrep.com/patent/US6730707B2

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method of reducing intraocular pressure by administering pharmaceutical compositions comprising indole derivatives. The pharmaceutical compositions useful in this invention comprise indole derivatives and melatonin analogs of Formulae I-IV. A preferred embodiment is a method of lowering intraocular pressure using 5-(methoxycarbonylamino)-N-acetyltryptamine (5-MCA-NAT), also known as GR 135531, which has a prolonged duration of action and greater efficacy in lowering intraocular pressure compared to melatonin. The present invention further provides a method of treating disorders associated with ocular hypertension, and a method of treating various forms of glaucoma; the method comprises administering an effective dose of a pharmacuetical composition comprising an indole derivative with or without agents commonly used to treat such disorders.

## Claims

### Claim 1

A method of reducing intraocular pressure in a subject in need thereof, said method comprising:
administering to said subject an indole derivative in an amount effective to reduce intraocular pressure, wherein said indole derivative is a compound of Formula I:
wherein:
n=0, 1, 2, 3, 4, or 5;
m=0 or 1;
R1 and R2 are each independently H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, -aryl, -aralkyl, -aralkenyl, -aralkynyl, R6(CO)—, F, OR5, or either R1 or R2 is R6R7N(CO)—; or R1 and R2 when taken together is oxo; or a substituted or unsubstituted carbocycle, or heterocycle of 4, 5, 6, or 7 members;
R3 and R4 are each independently H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, -aryl, -aralkyl, -aralkenyl, -aralkynyl, R6(CO)-,
or R3 and R4 when taken together is oxo; or a substituted or unsubstituted carbocycle or a heterocycle of 4, 5, 6, or 7 members;
or R2 and R4 when taken together represent a substituted or unsubstituted carbocycle or heterocycle of 4, 5, 6, or 7 members;
A=, NO2, CN or R5—X1—;
B=halogen, NO2, CN, H, or R5-X1-;
when B is not equal to halogen, NO2, CN or H, then B taken together with R1 represent a substituted or unsubstituted carbocyclic or heterocyclic ring of 5, 6, or 7 members;
when B is not equal to halogen, NO2, CN or H, and when B is in position 7 of the indole, then B optionally taken together with E represent a substituted or unsubstituted heterocyclic ring of 5, 6, or 7 members;
X1=O, S, NR9, —CF2—, —CH2—, —CH2CH2-, -CH2CH2CH2-, or absent;
R5=H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, -aryl, -aralkyl, -aralkenyl, -aralkynyl, R6R7N(CO)—, R6(CO)—, R8O(CO)—, R8S(O)2—, R8S(O)—, R8OS(O)2—, R8S(O)—, R6R7NS(O)2—, R6R7NP(O)(OR9)—, R8P(O)(OR9)—, (R8O)P(O)(OR9)—, or CF3—;
provided that when E=H, D1=R5—X1 and X1=O, or —CH2—, or —CH2CH2—, or—CH2CH2CH2—, then R5 is not H, or aryl;
R6 and R7 are independently H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, -aryl, -aralkyl, -aralkenyl, -aralkynyl or heterocyclic ring; when taken together, NR6R7 represent a substituted or unsubstituted ring of 3, 4, 5, 6, or 7 members;
R8=substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, aryl, -aralkyl, -aralkenyl, -aralkynyl, heterocyclic ring or CF3—;
R9=H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, aryl, -aralkyl, -aralkenyl, -aralkynyl;
when taken together, R6 and R9 represent a ring of 5, 6, or 7 members;
when B is in position 4 of the indole, B and Z1 taken together represent a substituted or unsubstituted heterocyclic ring of 5, 6, or 7 members;
when B is in position 4 of the indole B and R1 taken together) represent a substituted or unsubstituted carbocyclic or heterocyclic ring of 5, 6, or 7 members;
E=H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, aryl, -aralkyl, -aralkenyl, -aralkynyl, R8O(CO)—, R8S(O)2—, or OR6;
or E=R6(CO)—, provided that when Z1=NR10R11, one of R10 or R11 is H;
or E=R6(CO)—, provided that when Z1=OR5, R5 is not H, alkyl, aryl, or aralkyl;
or E=R6R7N(CO)—, provided that when Z1=NR10R11, one of R10 or R11 is H;
or E=R6R7N(CO)—, provided that when Z1=OR5, R5 is not H, alkyl, aryl, or aralkyl;
D1=halogen, NO2, CN or R5—X1—;
D1 and E when taken together represent a substituted or unsubstituted heterocyclic ring of 4, 5, 6, or 7 members;
D1 and R1 when taken together represent a substituted or unsubstituted carbocyclic or heterocyclic ring of 5, 6, or 7 members;
D1 and R3 when taken together represent a substituted or unsubstituted carbocyclic or heterocyclic ring of 5, 6, or 7 members;
D1 and Z1 when taken together represent a substituted or unsubstituted heterocyclic ring of 5, 6, or 7 members;
Z1=OR5 or NR10R11;
Z1 and R1 when taken together represent a substituted or unsubstituted heterocycle of 4, 5, 6, or 7 members;
R10=H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, -alkenyl, -alkynyl, aryl, -aralkyl, -aralkenyl, -aralkynyl, heterocycle, R6R7N(CO)—, R6(CO)—, R8O(CO)—, R8S(O)2—, R8OS(O)2—, R6R7NS(O)2—, CF3—; and
R11=NR6R7(CO)—, R6(CO)—, R8O(CO)—, R8S(O)2—, R8OS(O)2—, R6R7NS(O)2—;
alternatively, D1 and R6 are absent and the carbonyl participates in a ring bridging the two positions; provided that when n=0, m=1, R5=CH3, X1=O, B=D1=E=R3=R4=H, then Z is not —NHAc.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said indole is a compound of Formula II:
wherein Z2 and Z3 are independently R6R7N(CO)—, R6(CO)—, R8O(CO)—, R8S(O)2—, R8OS(O)2—, R6R7NS(O)2—; or each unit Z2—N—R10, and Z3—N—R10 independently represent a ring of 4-7 members.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said indole is a compound of Formula III:
wherein D1 is defined as in claim 1 or alternately D1 forms a ring with R6, or alternately D1 and R6 are absent and the carbonyl participates in a ring bridging the two positions.

### Claim 4 (depends on 3)

The method according to claim 3 wherein B=D1=E=H.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said indole is a compound of Formula IV:
D2=H, substituted or unsubstituted linear-, branched- or cyclo-alkyl, halogen, substituted or unsubstituted phenyl, or substituted or unsubstituted arylalkyl; provided when R5=R6=CH3, then D2 is not equal to H.

### Claim 6 (depends on 5)

The method according to claim 5 wherein R5=C1-C4 alkyl, acetyl, formyl or CF3; R6=H, C1-C4 alkyl, or CF3; provided when R5=CH3, then R6 is not CH3.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said compound is administered in an amount effective to achieve a concentration thereof on the ocular surface of said subject of from about 10−12M to 10−3M.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said compound is 5-methoxycarbonylamino-N-acetyltryptamine.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said indole is selected from the group of compounds consisting of N-[2-(5-Dimethylamino-1H-indol-3-yl)-ethyl]-acetamide, {3-[2-(2-Hydroxy-benzylamino)-ethyl]-1H-indol-5-yl}-carbamic acid methyl ester, [3-(2-Acetylamino-ethyl)-2-phenyl-1H-indol-5-yl]-carbamic acid methyl ester, [3-(2-Acetylamino-ethyl)-1-methyl-1H-indol-5-yl]-carbamic acid methyl ester, [3-(3-Acetylamino-propyl)-1H-indol-5-yl]-carbamic acid methyl ester, [3-(3-Benzenesulfonylamino-propyl)-1H-indol-5-yl]-carbamic acid methyl ester, N-[2-(5-Ureido-1H-indol-3-yl)-ethyl]-acetamide, [3-(2-Propionylamino-ethyl)-1H-indol-5-yl]-carbamic acid methyl ester, N-[2-(5-Methoxycarbonylamino- 1H-indol-3yl)-ethyl]-succinamic acid, [3-(2-Acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid allyl ester, [3-(2-Acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid 3-hydroxy-propyl ester, [3-(2-Acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid 2,3-dihydroxy-allyl ester, and N-[3-(2-Acetylamino-ethyl)-1H-indol-5-yl]-acetamide, [3-(2-Acetylamino-ethyl)-2-bromo-1H-indol-5-yl]-carbamic acid methyl ester, [3-(2-Acetylamino-ethyl)-2-methyl-1H-indol-5-yl]-carbamic acid methyl ester, [3-(2-Acetylamino-ethyl)-1-benzyl-1H-indol-5-yl]-carbamic acid methyl ester, (1-Oxo-2,3,4,9-tetrahydro-1H-β-carbolin-6-yl)- carbamic acid methyl ester, and [3-(2-Acetylamino-ethyl)-4-(1-methoxy-ethyl)-1-methyl-1H-indol-5-yl]-carbamic acid methyl ester.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said indole derivative of Formula I is administered to a subject in need of treatment, to treat a condition selected from the group consisting of ocular hypertension and glaucoma, in and amount effective to treat said condition.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said glaucoma is primary glaucoma.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said primary glaucoma is selected from the group consisting of narrow-angle, acute congestive glaucoma; wide-angle, chronic simple glaucoma; and secondary glaucoma.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said indole derivative is co-administered with therapeutic and adjunctive agents used to manage narrow angle, acute congestive glaucoma, selected from the group consisting of: anticholinesterase inhibitors, carbonic anhydrase inhibitors, prostaglandin analogues, and osmotic agents.

### Claim 14 (depends on 13)

The method according to of claim 13, wherein said anticholinesterase inhibitor is salicylate or pilocarpine nitrate; said carbonic anhydrase inhibitor is acetazolamide; said prostaglandin analogue is Xalatan or bimatoprost; and said osmotic agent is mannitol or glycerin.

### Claim 15 (depends on 1)

The method according to claim 1, wherein said indole is co-administered with therapeutic agents used to manage wide angle, chronic simple glaucoma, and is selected from the group consisting of parasympathomimetic agents, short-acting anticholinesterase agents, long-acting anticholinesterase agents, alpha-adrenergic agonists, beta-adrenergic antagonists, sympathomimetic agents, and prostaglandin analogues.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said parasympathomimetic agent is pilocarpine nitrate; said short-acting anticholinesterase inhibitor is physostigmine salicylate; said long-acting anticholinesterase inhibitor is demecarium bromide, echothiophate iodide or isofluorophate; said beta adrenergic antagonist is timolol maleate; said sympathomimetic agent is epinephrine or phenylephrine; and said prostaglandin analogue is latanoprost or bimatoprost.

### Claim 17 (depends on 12)

The method according to claim 12, wherein said indole derivative is co-administered with therapeutic agents used to manage secondary glaucoma, and selected from the group consisting of: parasympathomimetic agents, short-acting anticholinesterase agents, long-acting anticholinesterase agents, beta-adrenergic antagonists, sympathomimetic agents, and prostaglandin analogues.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said parasympathomimetic agent is pilocarpine nitrate; said short-acting anticholinesterase inhibitor is physostigmine salicylate; said long-acting anticholinesterase inhibitor is demecarium bromide, echothiophate iodide or isofluorophate; said beta adrenergic antagonist is timolol maleate; said sympathomimetic agents is epinephrine or phenylephrine; and said prostaglandin analogue is latanoprost or bimatoprost.

### Claim 19 (depends on 1)

The method according to claim 1, wherein said indole derivative is administered in a sterile preparation comprising said compound or pharmaceutically acceptable salts thereof together with a pharmaceutically acceptable vehicle or carrier therefor.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said pharmaceutically acceptable carrier is a physiologically compatible vehicle selected from the group consisting of: aqueous electrolyte solutions, polyethers, polyvinyls, polymers of acrylic acid, lanolin, and glucosaminoglycans, whereby said formulation enhances outflow of fluid from the eye and thereby reduces intraocular pressure.

### Claim 21 (depends on 1)

The method according to claim 1, wherein said method of administering said compound is selected from the group consisting of a) topical administration via a carrier vehicle selected from a group consisting of, drops of liquid, liquid wash, gels, ointments, sprays and liposomes; b) infusion to said ocular surface via a device selected from a group consisting of, a pump-catheter system, a continuous or selective release device, and a contact lens; and c) systemic administration.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said systemic administration of said indole is accomplished by administering an intra-operative instillation of a gel, cream, powder, foam, crystals, liposomes, spray, drops of liquid, or liquid suspension form of said compound, such that a therapeutically effective amount of said compound contacts the ocular tissues of said subject via systemic absorption and circulation.

### Claim 23 (depends on 1)

The method according to claim 1, wherein said indole derivative is used to reduce adverse side effects of drugs used to treat glaucoma, comprising the step of:
administering said indole derivative with a drug selected from the group consisting of: demecarium, echothiophate and isofluorophate.

### Claim 24

A composition comprising a compound selected from the group consisting of:[3-(2-acetylamino-ethyl)-2-methyl-1H-indol-5-yl]-carbamic acid methyl ester; [3-(2 -acetylamino-ethyl)-2-phenyl-1H-indol-5-yl]-carbamic acid methyl ester;[3-(3-acetylamino prop-1-yl)-1H-indol-5-yl]-carbamic acid methyl ester;N-[2-(5-methoxycarbonylamino-1H-indol-3-yl)-ethyl]-succinamic acid;[3-(2-acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid allyl ester;[3-(2-acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid 3-hydroxy-prop-1-yl ester; [3-(2-acetylamino-ethyl)-1H-indol-5-yl]-carbamic acid 2,3-dihydroxy-allyl ester; [3-(2-acetylamino-ethyl)-4-(1-methoxy-ethyl)-1-methyl-1H-indol-5-yl]-carbamic acid methyl ester N-[3-(2-acetylamino-ethyl)- 1H-indol-5-yl]-acetamide; [3-(2-acetylamino-ethyl)-1-benzyl-1H-indol-5-yl]-carbamic acid methyl ester; and (1-oxo-2,3,4,9-tetrahydro-1H-β-carbolin-6-yl)-carbamic acid methyl ester, and pharmaceutically acceptable vehicle or carrier.
